Ambicare Health Ltd., the Scottish developer of light-based devices for the treatment of an array of medical and cosmetic skin conditions, announced today that it had successfully been awarded clearance by the US Food and Drug Administration (FDA) for the over-the- counter sale of its Lustre Pure LIght system for the treatment of mild to moderate acne, spots and pimples.

This is an important validation of Ambicare’s patented, wearable technology using ‘blue light’ emanating from LED’s. Unlike other blue light devices, the acne sufferer can attach the device’s treatment heads to the affected areas and then go about his or her daily routine, rather than sitting in front of a static LED array or holding a hand-held unit, moving it from area to area.

The ambulatory nature of Ambicare’s Lustre Pure Light device allows it to operate at lower, more comfortable power settings ensuring effective treatment.
Lustre Pure Light has been on sale for the past year on Boots.com, in leading Boots stores and on-line. The company now intends to accelerate discussions with potential marketing partners in the United States, the world’s biggest market for acne treatment.

For further information, please contact:
Graeme Low
Chief Executive
Ambicare Health Ltd
e: graeme.low@ambicarehealth.com
t: +44(0)1506 59 2242
m: +44 (0)7803 438703

If you have found this post interesting, please share it with your online community, using either Twitter, Facebook or the share buttons below. Thank You.